Reviewer’s report

Title: Using electronic medication monitoring to guide differential management of tuberculosis patients at the community level in China

Version: 1 Date: 16 Sep 2019

Reviewer: Richard Garfein

Reviewer's report:

The authors did an excellent job of responding to the reviewers' comments and the additional editorial review substantially improved the readability of the paper. Other than the comment below, all of my prior comments were appropriately addressed.

My only 1 remaining critique relates to the definition of "BMU". The revised text "Data were collected on variables such as TBIMS code for basic management unit (BMU) (which is established at the county level in China, in contrast to TB management units, which are established at the provincial, prefecture and county levels),..." seems to differentiate a BMU from a "TB management unit", but still does not help the reader to understand what these units are. Are they clinics, hospitals, or governmental administrative units with TB control responsibilities (e.g., health departments)?

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I am co-founder of SureAdhere Mobile Technology, which produced a commercial video directly observed therapy (VDOT) app for monitoring anti-TB treatment. Since the EMM technology in this paper does not compete directly with VDOT, I would not expect to gain or lose financially from the publication of this manuscript.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal